RecruitingPhase 2NCT07521137

Biweekly Long-term Occidiofungin Study for Suppression of Mycotic Recurrence

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women With Acute Vulvovaginal Candidiasis

Sponsor

Sano Chemicals Inc

Enrollment

36 participants

Start Date

Jun 4, 2026

Study Type

INTERVENTIONAL

Conditions

Candidiasis, Vulvovaginal

Summary

A Randomized, Double-Blind, Placebo-Controlled Phase 2a Study Evaluating the Safety, Tolerability, and Efficacy of OCF001 Intravaginal Gel in Women with Acute Vulvovaginal Candidiasis

Eligibility

Sex: FEMALEMin Age: 18 YearsMax Age: 65 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying a drug called OCF001 Intravaginal Gel and a drug called Placebo Gel for people with candidiasis, vulvovaginal. The study is currently recruiting participants at 1 location. People eligible for this study include women aged 18 Years to 65 Years.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DRUGOCF001 Intravaginal Gel

OCF001 is an antifungal antibiotic that is formulated in a water-miscible viscous gel at concentrations of 0.150 mg / g of gel.

DRUGPlacebo Gel

Placebo (Gel formulation without OCF)

Locations(1)

UAB Sexual Health Research Clinic

Birmingham, Alabama, United States

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT07521137

Related Trials

Vulvovaginal Candidiasis in Canadian Females

NCT049301071 location

The Effect of Medical Grade Honey Formulation (L-Mesitran) Administration on Recurrent Vulvovaginal Candidiasis Symptoms

NCT053670892 locations